Bilastine in allergic rhinoconjunctivitis and urticaria

  title={Bilastine in allergic rhinoconjunctivitis and urticaria},
  author={Claus Bachert and Pavel Kuna and T Zuberbier},
To cite this article: Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010; 65 (Suppl. 93): 1–13. 

Bilastine in symptomatic allergic rhinoconjunctivitis and urticaria: a guide to its use

Bilastine has a favourable pharmacological profile, with a rapid onset of action and sustained efficacy over the 24-h dosing interval period, as well as a lack of CNS and cardiotoxic effects and clinically relevant drug interactions.

Up-dosing with bilastine results in improved effectiveness in cold contact urticaria

The effects of a standard 20 mg dose and up‐dosing to 40 and 80 mg of bilastine in reducing the symptoms of CCU and inflammatory mediator release following cold challenge are assessed.

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria

During clinical development, bilastine was shown to be a drug that is adequately tolerated, with a similar effect to placebo with regard to drowsiness and changes in heart rate, and headaches were the most frequent adverse effect to be reported.

Effect of bilastine upon nasal obstruction.

The analysis of the data from the different clinical trials indicates that in patients with allergic rhinitis, the effect of bilastine upon nasal obstruction is superior to that of placebo and similar to those of other second-generation H1 antihistamines, manifesting within 24 hours after the start of treatment.

Bilastine: in allergic rhinitis and urticaria.

Bilastine was generally well tolerated, with a tolerability profile that was generally similar to that of the other second-generation antihistamines included in phase III clinical trials.

Chronic Urticaria

Current international guidelines recommend the use of non-sedating antihistamines as the first choice in therapy and up-dosing these up to fourfold in cases ofnon-response.

An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria

Clinical studies in allergic rhinitis and chronic urticaria show that once-daily treatment with bilastine 20 mg is effective in managing symptoms and improving patient’s quality of life, with at least comparable efficacy to other nonsedative H1-antihistamines.

Bilastine for the treatment of urticaria

Once-daily treatment with bilastine 20 mg is effective in managing symptoms and improving patient's quality of life in chronic urticaria, with at least comparable efficacy to levocetirizine.

Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review

Whether bilastine meets the criteria defined in the European Academy of Allergy and Clinical Immunology (EAACI)/ARIA proposals for oral H1-antihistamines for medications used in the treatment of allergic rhinitis is examined.

Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria

  • M. Church
  • Medicine
    Expert opinion on drug safety
  • 2011
Bilastine has high selectivity for H1-receptors, is rapidly and effectively absorbed, undergoes negligible metabolism and is a substrate for P-glycoprotein, which limits its passage across the blood–brain barrier.



Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study

  • P. KunaC. Bachert R. Valiente
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2009
Background Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).

Urticaria and infections

  • B. WediU. RaapD. WieczorekA. Kapp
  • Medicine, Biology
    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
  • 2009
This review will update the reader regarding the role of infections in different urticaria subtypes and since infections can be easily treated some diagnostic procedures should be included in the routine work-up, especially the search for Helicobacter pylori.

Chronic Urticaria: Recent Advances

It is now recognized that chronic “idiopathic” urticaria includes a subset with an autoimmune basis caused by circulating autoantibodies against the high affinity IgE receptor (FceR1) and less commonly against IgE.

EAACI/GA2LEN/EDF/WAO Guideline:Management of Urticaria

The recommended first line treatment of urticaria is new generation, nonsedating H1-antihistamines, and second-line therapies should be added to the antihistamine treatment, both their costs and risk/benefit profiles are most important to consider.

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi‐centre, double‐blind, randomized, placebo‐controlled study

To cite this article: Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R, the Bilastine International Working Group. Comparison of the efficacy and safety

The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study and had a rapid onset of action within 1 h, and a long duration of action, greater than 26 h.

Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

This document updates the ARIA sections on the pharmacologic and anti‐IgE treatments of allergic rhinitis and only a few studies assessing nasal and non‐nasal symptoms are presented.

EAACI/GA2LEN/EDF guideline: management of urticaria

The recommended first line treatment are nonsedating H1 antihistamines, but dosages increased up to fourfold over the recommended doses may be necessary for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment.

The burden of rhinitis: nothing to sniff at.

  • E. Weir
  • Medicine
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2003
It is the little things in life that, when counted, start to add up — the service charge on banking transactions, the second glass of wine with dinner, the antihistamine taken for the stuffed-up nose.

Consensus statement * on the treatment of allergic rhinitis

Current guidelines emphasize the importance of an accurate diagnosis of patients presenting with rhinitis symptoms and the morbidity of SAR obviously depends on the geographic region, the pollen season of the plants, and the local climate.